The CYB5R3 T117S missense variant is associated with attenuated riociguat efficacy in sickle cell disease.

The CYB5R3 T117S variant reduces riociguat efficacy by impairing nitric oxide signaling in sickle cell disease patients.

• Why it matters: Understanding genetic factors that influence drug response is crucial for improving treatment outcomes in sickle cell disease, where nitric oxide signaling is compromised.
• What they did: The study examined the association between the CYB5R3 T117S missense variant and riociguat effectiveness, focusing on its role in regulating soluble guanylyl cyclase activity.
• The result: Findings show the T117S variant correlates with decreased riociguat response, suggesting genetic screening could optimize therapeutic strategies for affected individuals.